CAS 2162962-69-6

Fórmula: C16H13NO2

InChI: InChI=1S/C16H13NO2/c1-10-8-11(2-5-16(10)19)13-6-7-17-15-9-12(18)3-4-14(13)15/h2-9,18-19H,1H3

Clave InChI: QXFYDRYRLOHSBD-UHFFFAOYSA-N

SMILES: CC1=C(C=CC(=C1)C2=C3C=CC(=CC3=NC=C2)O)O

4-(4-Hydroxy-3-Methylphenyl)Quinolin-7-Ol

CAS: 2162962-69-6

Fórmula: C₁₆H₁₃NO₂

Pureza: 97%

Forma y color: Solid

Peso molecular: 251.2799

Ref: IN-DA01EOJW

4-(4-Hydroxy-3-Methylphenyl)Quinolin-7-Ol

CAS: 2162962-69-6

4-(4-Hydroxy-3-Methylphenyl)Quinolin-7-Ol

Fórmula: C₁₆H₁₃NO₂

Pureza: 97%

Peso molecular: 251.28

Ref: 54-OR1024147

CU-CPT9b

CAS: 2162962-69-6

CU-CPT9b

Fórmula: C₁₆H₁₃NO₂

Pureza: ≥98%

Peso molecular: 251.28

Ref: 54-BUP03596

CU-CPT9b

CAS: 2162962-69-6

CU-CPT9b (TLR8-specific antagonist 1) is an antagonist of toll-like receptor 8 (TLR8; Kd = 21 nM).

Fórmula: C₁₆H₁₃NO₂

Pureza: 98.1%

Forma y color: Solid

Peso molecular: 251.28

Ref: TM-T7302

CU-CPT9b

CAS: 2162962-69-6

4-(4-Hydroxy-3-methylphenyl)quinolin-7-ol

Fórmula: C₁₆H₁₃NO₂

Pureza: 97%

Peso molecular: 251.28

Ref: IN-DG00784285

CU-CPT9b

CAS: 2162962-69-6

CU-CPT9b is a potent compound that has been shown to have clinical relevance in the treatment of autoimmune diseases. CU-CPT9b is a ligand that binds to toll-like receptor 4 (TLR4) and inhibits TLR4 signaling, which is involved in the activation of immune cells. CU-CPT9b has been shown to be effective against inflammatory diseases such as rheumatoid arthritis and multiple sclerosis, but not against other types of autoimmune diseases such as type 1 diabetes or systemic lupus erythematosus. CU-CPT9b also has a high efficacy in a mouse model system for type 1 diabetes, with no adverse effects on body weight or food intake. In addition, CU-CPT9b has been found to be safe in clinical trials involving human subjects with inflammatory bowel disease.

Fórmula: C₁₆H₁₃NO₂

Pureza: Min. 95%

Peso molecular: 251.28 g/mol

Ref: 3D-MLD96269